StrataXRT®硅酮凝胶预防头颈癌放射性皮炎的随机对照试验
一项单盲随机对照优效性试验纳入197例接受根治性放疗(≥50 Gy)的头颈癌患者,比较StrataXRT®与10%甘油霜(Sorbolene)对放射性皮炎的预防和管理效果。结果显示StrataXRT®组放疗结束时平均皮肤毒性更低(P=0.002),2级和3级皮肤毒性发生率更低,调整西妥昔单抗后2级和3级风险分别降低12%和36%,但患者报告结局无差异。
要点
- StrataXRT®组放疗结束时平均皮肤毒性显著低于Sorbolene组(P=0.002)。
- 调整西妥昔单抗后,StrataXRT®组2级皮肤毒性风险降低12%(RRR=0.876,95%CI 0.778-0.987,P=0.031),3级降低36%(RRR=0.648,95%CI 0.442-0.947,P=0.025)。
- 两组患者报告结局无差异,且均无治疗中断和研究产品相关不良事件。
核心结论
- StrataXRT®可有效预防并延缓头颈癌放疗患者2级和3级皮肤毒性的发生。
研究设计与样本
- 单盲、随机对照、优效性试验,纳入197例接受根治性放疗(≥50 Gy)伴或不伴化疗或生物治疗的头颈癌患者,比较StrataXRT®与10%甘油霜(Sorbolene)。
主要发现
- 放疗结束时StrataXRT®组平均皮肤毒性低于Sorbolene组(P=0.002)。
- 放疗结束时StrataXRT®组2级皮肤毒性发生率为80%、3级为28%,Sorbolene组分别为91%和45%。
- 调整西妥昔单抗后,StrataXRT®组2级皮肤毒性风险降低12%(RRR=0.876,95%CI 0.778-0.987,P=0.031),3级降低36%(RRR=0.648,95%CI 0.442-0.947,P=0.025)。
- Cox回归分析显示StrataXRT®组治疗期间发生2级和3级皮肤毒性的风险分别降低41.0%和49.4%。
- 两组患者报告结局无差异,均无治疗中断和研究产品相关不良事件。
临床怎么用
- 对于接受根治性放疗(≥50 Gy)的头颈癌患者,可考虑使用StrataXRT®硅酮凝胶预防和管理2级及3级放射性皮炎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Investigate the effects of StrataXRT® versus 10% Glycerine (Sorbolene cream) for preventing and managing radiation dermatitis in patients with head and neck cancer receiving radical radiotherapy (≥50 Gy) with or without chemotherapy or biotherapy. METHODS: A single-blind, randomised controlled, superiority trial was conducted. Patients either received StrataXRT® or Sorbolene (usual care). Skin toxicity, pain, itching and skin-related quality of life scores were collected from baseline, and up to four weeks post-treatment. RESULTS: A total of 197 patients were randomised into the study. Skin toxicity was dependent on the treatment group with StrataXRT® patients experiencing lower mean skin toxicity at the end of the radiation treatment (P = 0.002). At the end of treatment, the StrataXRT® arm had a lower percentage of grade 2 (80%) and grade 3 (28%) skin toxicity compared to the sorbolene arm (91% and 45% respectively). After adjustment for Cetuximab, the StrataXRT® arm had a 12% lower risk of experiencing grade 2 skin toxicity (RRR = 0.876, 95% CI: 0.778-0.987, P = 0.031); and a 36% lower risk of experiencing grade 3 skin toxicity (RRR = 0.648, 95% CI: 0.442-0.947, P = 0.025). Cox regression analysis showed that patients receiving StrataXRT® had a 41.0% and 49.4% reduced risks of developing grade 2 and 3 skin toxicity respectively throughout treatment compared to the Sorbolene arm. There were no differences between groups in patient-reported outcomes. No treatment interruptions and study product related adverse events were reported in either arm. CONCLUSION: StrataXRT® is effective for preventing, and delaying the development of grade 2 and 3 skin toxicity. TRIAL REGISTRATION: ACTRN12616000511437.
引用
- Chan RJ, Blades R, Jones L, et al. A single-blind, randomised controlled trial of StrataXRT® - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Radiother Oncol. 2019. PMID: 31445838. doi:10.1016/j.radonc.2019.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。